報價延遲最少15分鐘:2025/07/18 07:04 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.86
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.76/0.03
|
|
企業價值
291.56M
|
| 資產負債 |
|
每股賬面淨值
8.68
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
198.77M
|
|
每股收益
4.04
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/18 07:04 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada. |
